Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights.Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights
Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Global LAG 3 Inhibitors Market Dynamics
- Clinical Approaches to Target LAG 3 Inhibitors
- Number of LAG 3 Inhibitors Drug In Trials
- LAG 3 Inhibitors Approved Patent Insight
- LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
- Company Agreement/Partnership/Deals For Ongoing Trials
- LAG-3 Targeted Approach in Cancer Therapy
- Therapeutic Approaches for Novel LAG-3 Targeted Therapy
- Global LAG 3 Inhibitor Market Future Outlook
Download Report:
Cancer immunotherapies targeting inhibitory receptors such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) have entered the market and have shown huge clinical success in enhancing the outcomes of patients with diverse cancer types. However, response rates are typically lower and immune related adverse events were also observed in patients administered with immune checkpoint inhibitors. Therefore, researchers believed that there is continuous need to decipher the complex biology of inhibitory coreceptors to increase response rate and prevent side effects in cancer patients.
Among several identified coreceptors, lymphocyte activation gene-3 (LAG-3) is the most promising target. LAG-3 is a member of immunoglobulin superfamily and a CD4 ancestor homolog. As an immune checkpoint, LAG-3 inhibits the activation of its host cells and generally promotes a more suppressive immune response. In cancer cells, LAG-3 is expressed on the cell membranes of TIL, activated CD4+ and CD8+ T-cells, as well as Tregs. Further, it is also expressed on NK cells, B-cells, and dendritic cells. Since its discovery and critical role in cancer, researchers have conducted several preclinical studies which concluded that the blockade of LAG-3 could support anti-cancer immune response, leading to significant delay in tumor growth compared to control conditions.
Recently in March 2022, US FDA has approved Opdualag developed by Bristol Myers Squibb in patients aged 12 years or over with unresectable or metastatic melanoma. Opdualag is the LAG-3 drug relatlimab as a fixed dose combination with its PD-1 inhibitor Opdivo (nivolumab). LAG-3 and PD-1 are two distinct inhibitory immune checkpoints which are more commonly co-expressed on tumor infiltrating lymphocytes, thus contributing to tumor mediated T-cell exhaustion. The combination of nivolumab and relatlimab has shown to increase T-cell activation in comparison to monotherapy treatment.
The novel drug was approved on the basis of promising results from phase-III Relativity-047 trial in unresectable or metastatic melanoma. The results from the trial demonstrated significant improve in progression free survival in patients having combinational therapy rather than monotherapy approach. Moreover, there were no treatment related adverse events reported. The most commonly occurring adverse events were elevated liver enzymes and fatigue, each of which occurred in just over 1% of patients.
As per Kuick Research, Opdualag will show high adoption rates in the market as it is the first new checkpoint target to reach patients since the first PD-1 drugs were approved in 2014. It is suggested that the approval of drug can be beginning of a series of new immune checkpoint inhibitor therapy. Apart from melanoma, several clinical trials are also evaluating the role of relatlimab in other cancers including hepatocellular carcinoma, soft tissue sarcoma, lymphoma, head and neck cancer, non-small cell lung cancer, ovarian cancer, and others.
Apart from this, several other LAG-3 inhibitors are showing encouraging response in the initial clinical trial. For instance, FS118 developed by F-Star Therapeutics is a dual checkpoint inhibitor targeting PD-1 and LAG-3 that drives LAG-3 shedding and receptor down-regulation, via bispecific activity. The results from phase-I data show encouraging response of FS-118 with no treatment related adverse events. The other major LAG-3 inhibitors in clinical development include Tebotelimab, LAG525, TSR-033, ABL501, amongst others.
The global LAG-3 inhibitor market is highly competitive and consists of several key players including Novartis, Bristol Meyer Squibb, Regenron, Boehringer Ingelheim, I-Mab Biopharma, and others. Mergers and acquisitions are being used by a huge number of companies to increase their geographical reach and proprietary knowledge. For instance in 2021, BeiGene and Nanijing Lead Biolabs nnounced entry into a license and collaboration agreement granting BeiGene worldwide research, development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.
It is estimated that there are currently more than 100 ongoing clinical trials which are accessing the role of novel LAG-3 inhibitors in wide range of cancers and several studies are being conducted at preclinical level. US is expected to dominate the global LAG-3 inhibitor which is mainly due to rapid approval of Relatlimab, large number of ongoing clinical trials and presence of major pharmaceutical giants in the region. Apart from this, increasing awareness among the individuals, high adoption rates of immunotherapeutic drugs, favorable reimbursement policies, and increasing initiatives by government will also drive the growth of the market in the region.
The rising awareness regarding cancer and availability of various immunotherapeutic approaches and innovative diagnostic tools for detecting cancer will boost the global LAG-3 inhibitor market. The rising investments by the biopharmaceutical industry players in the research and clinical trials of various therapeutics and diagnostics will further drive the growth of market during the forecast period. The report provides comprehensive insights on the ongoing clinical trials in the market, major drugs in research and development, and therapeutic approaches for novel LAG-3 targeted therapy. The ongoing company agreement, partnerships or deals in the global market is also included in the report. The report also discuss on the available patents for the novel LAG-3 inhibitors in clinical trial.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366